Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Allogene Therapeutics Inc ALLO

Healthcare Biotechnology
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on four core programs: Large B-Cell Lymphoma (LBCL), Chronic Lymphocytic Leukemia (CLL), Autoimmune Disease and Renal Cell Carcinoma. It is developing a... see more

Recent & Breaking News (NDAQ:ALLO)

Allogene Therapeutics Announces Three Poster Presentations from its Next Generation AlloCAR T(TM) Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

GlobeNewswire September 27, 2023

Allogene Therapeutics Announces Participation in September Investor Conference

GlobeNewswire September 5, 2023

Allogene Therapeutics Appoints Earl Douglas as General Counsel

GlobeNewswire August 14, 2023

Allogene Therapeutics Reports Second Quarter 2023 Financial Results and Business Update

GlobeNewswire August 2, 2023

Allogene Therapeutics to Report Second Quarter 2023 Financial Results on August 2, 2023

GlobeNewswire July 26, 2023

Allogene Therapeutics Provides Additional ALLO-501/501A Phase 1 Data in an Oral Presentation at the International Conference on Malignant Lymphoma (ICML) Lugano

GlobeNewswire June 15, 2023

Allogene Therapeutics Announces Departure of Chief Financial Officer

GlobeNewswire June 14, 2023

Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-501/501A in Large B Cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) Lugano

GlobeNewswire June 9, 2023

Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire June 3, 2023

Allogene Therapeutics Announces Participation in Three Upcoming Investor Conferences

GlobeNewswire May 24, 2023

Allogene Therapeutics Announces Encore Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the European Hematology Association (EHA) Hybrid Congress

GlobeNewswire May 11, 2023

Allogene Therapeutics Reports First Quarter 2023 Financial Results and Business Update

GlobeNewswire May 3, 2023

Allogene Therapeutics Announces Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire April 26, 2023

Allogene Therapeutics to Report First Quarter 2023 Financial Results on May 3, 2023

GlobeNewswire April 25, 2023

Allogene Therapeutics Appoints Timothy Moore as Chief Technical Officer

GlobeNewswire April 20, 2023

Allogene Therapeutics Presents Interim Phase 1 Data on ALLO-316 in Renal Cell Carcinoma at the American Association of Cancer Research (AACR) Annual Meeting

GlobeNewswire April 17, 2023

Allogene Therapeutics Announces Participation in Four Upcoming Investor Conferences

GlobeNewswire April 13, 2023

Allogene Therapeutics Publishes 2022 Annual Environmental, Social and Governance (ESG) Report

GlobeNewswire March 30, 2023

Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-316 at the American Association of Cancer Research (AACR) Annual Meeting

GlobeNewswire March 14, 2023

Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences

GlobeNewswire March 2, 2023